Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia

23 Jan 2015

Abstract excerpt

OBJECTIVE: Lp(a) is an independent, causal, genetic risk factor for cardiovascular disease and aortic stenosis. Current pharmacological lipid-lowering therapies do not optimally lower Lp(a), particularly in patients with familial hypercholesterolemia (FH). APPROACH AND RESULTS: In 4 phase III trials, 382 patients on maximally tolerated lipid-lowering therapy were randomized 2:1 to weekly subcutaneous mipomersen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis and Cardiovascular Diseases
Share to HIV-related health complications and treatments
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25614280
DOI: 10.1161/atvbaha.114.304549

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaPMID 25614280Read ↗

Treatment of Lp(a): Is It the Future or Are We Ready Today?Semantic proximity Read ↗

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemiaSemantic proximity Read ↗

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?Semantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging TherapeuticsSemantic proximity Read ↗

Lipoprotein(a): more interesting than ever after 50 years.Semantic proximity Read ↗

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseSemantic proximity Read ↗

Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) MoleculeSemantic proximity Read ↗

Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.Semantic proximity Read ↗

Lipoprotein(a)Semantic proximity Read ↗

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.